Important Biotech Catalysts For September 14, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON)…
Eloxx Shares Plummet As Mid-Stage Cystic Fibrosis Study Results Miss Efficacy Endpoints
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced topline results from the Phase 2 clinical trial of ELX-02 in combination with ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation.
This Hepatitis Stock Has ‘Multiple Paths To Value Creation,’ Expects To Double, Bullish Analyst Predicts
SVB Leerink initiated coverage on Vir Biotechnology Inc (NASDAQ:VIR) with an Outperform rating and a price target of $40, with an investment…
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
As part of President Joe Biden’s executive order to beef up U.S. biomanufacturing, the U.S. Department of Health and Human…
Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims
A federal judge dismissed a whistleblower lawsuit accusing Novartis AG (NYSE: NVS) of paying doctors kickbacks at "sham" speaker programs to boost prescriptions of its multiple sclerosis blockbuster drug Gilenya.
Smith & Nephew’s Implant Shows 86% Reduction In Re-Tear Rates After Shoulder Surgery
Smith & Nephew plc (NYSE:SNN) announced new data furthering several published studies supporting the use of its REGENETEN Bioinductive Implant in…
Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds…
FDA Grants Orphan Drug Status To Centessa’s Hemophilia B Candidate
Centessa Pharmaceuticals (NASDAQ: CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B.
A Phase 2a proof-of-concept study evaluated SerpinPC in severe hemophilia A and B patients not on prophylaxis.
After One Year Of Regulatory Hold, Larimar’s Ataxia Candidate Sees Some Hope
The FDA has cleared the initiation of Larimar Therapeutics Inc’s (NASDAQ:LRMR) 25 mg cohort of Phase 2 trial of CTI-1601 in Friedreich’s…